• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Medical Cannabis for Chronic Pain and Quality of Life

Medical Cannabis for Chronic Pain and Quality of Life

February 3, 2021
Pavan Madan, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information
Pavan Madan, MD. Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
REVIEW OF: Safakish R et al, Pain Medicine 2020 Jun 18;pnaa163. Epub ahead of print.

Although chronic pain affects 10%–30% of the adult population and contributes to a host of physical and mental health problems, we often find ourselves with limited options to assist the patient with pain in front of us. While medical cannabis (MJ) has shown promise as a potential treatment option in smaller trials, the authors of the current study hoped to replicate the results in a larger population.

In this open-label, observational, longitudinal study, researchers recruited adults over 25 years old with chronic pain (defined as pain for over 3 months) at a cannabis clinic in Toronto, ­Canada. The authors followed these patients for 12 months and monitored their pain severity (via the Brief Pain Inventory [BPI], a 0–10 scale), the pain’s interference with quality of life (via the Short Form Health Survey [SFHS], a 0–100 scale), physical symptoms, and use of opioids. Prescribers personalized dosing and route using an average daily dose of 1.25–1.5 grams of dry cannabis flowers (approximately 3 joints).

Although 1,245 subjects initially signed up for the study, only 60% (n = 751) kept at least 1 follow-up appointment (and were analyzed), and just 3% (n = 43) attended the final 12-month follow-up. The mean age of participants was 49.6 years, and 43% were men. About half of the subjects reported one pain condition (47%), while the rest had multiple pain issues. The most commonly reported pain conditions were back pain (47%), osteoarthritis (28%), chronic headaches (21%), fibromyalgia (18%), and degenerative disc disease (16%).

At each follow-up appointment, patients reported significant improvement in pain severity (mean BPI score dropped from 5.58 at baseline to 3.49 at month 12, p < 0.001) and life interference (6.23 at baseline to 3.54 at month 12, p = 0.001) with continued MJ. The effect size was 0.30, which is considered medium.

Those who followed up in the study had reduced anxiety, fatigue, nausea, and headaches over a period of 12 months, and no major adverse events were reported. The authors found statistically significant improvement in physical and mental health–related quality of life measures on the SFHS (p < 0.05), but the change in the physical health–related index does not appear to be clinically meaningful (scores improved from 31+/-8 to 33+/-11).

Patients taking opioids at baseline reported a reduction in their opioid dosage over time; however, the sample size was too small to generalize results (from 84 at baseline to 4 at month 12).

CATR’S TAKE
In patients with chronic pain, medical cannabis may be associated with reduced pain, improved physical and emotional well-being, and even reduced opioid usage. However, given the lack of a control group and the high attrition rate in this study, we would like to see these results replicated in a larger, randomized controlled trial.
Addiction Treatment
KEYWORDS clinical-practice marijuana observational-study pain quality-of-life
Pavan Madan, MD.

The Evidence Base for Polypharmacy in ADHD

More from this author
www.thecarlatreport.com
Issue Date: February 3, 2021
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Pain and Addiction, CATR, January/February 2021
Kratom: A Primer
Supporting Patients With Pain and Addiction
Medical Marijuana for Chronic Pain: The Cart Before the Horse?
Medical Cannabis for Chronic Pain and Quality of Life
Do We Need to Be Face-to-Face to Treat Alcohol Use Disorder?
Featured Book
  • PracticeBoosters2e.JPG

    Psychiatry Practice Boosters, Second Edition (2018)

    Teaches you the key points of 42 of the most clinically relevant studies in psychiatry published...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • Substance_Use_Sites.jpeg
    Addiction Treatment

    Supervised Drug Consumption Sites

    Once controversial, research clearly shows the benefit of these sites, and they have started opening in the United States.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.